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Summary We have studied the long-term endocrine effects of treatment on 144 children treated for brain
tumours. All received cranial irradiation, 86 also received spinal irradiation and 34 chemotherapy. Almost all
patients (140 of 144) had evidence of growth hormone insufficiency. Treatment with growth hormone was
effective in maintaining normal growth but could not restore a deficit incurred by delay in instituting
treatment. The effect of spinal irradiation on spinal growth was not corrected by growth hormone. As spinal
growth makes the major contribution to the pubertal growth spurt and limb length the major contribution to
childhood growth, treatment with GH will have maximal effect on leg length if instituted before the onset of
puberty. Primary thyroid dysfunction was found in 11 of 47 children (23%) treated with craniospinal
irradiation but in none treated with cranial irradiation alone. The incidence rose to 69% of 29 children treated
with spinal irradiation and chemotherapy and to 50% of four children treated with cranial irradiation and
chemotherapy. This effect of chemotherapy has not previously been reported and was detected by us through
measurement of serum TSH concentration. Primary thyroid dysfunction requires treatment with thyroxine to
prevent increasing the risk of secondary thyroid tumours. Seven of 20 girls (35%) treated with spinal
irradiation had primary ovarian dysfunction as determined by raised gonadotrophin levels. Chemotherapy
increased this, but not significantly. Three of 15 boys (20%) treated with chemotherapy had primary testicular
dysfunction. Gonadotrophin deficiency occurred in seven boys. Four of 90 children had deficiency of cortisol
secretion in response to hypoglycaemia. These results confirm the requirement for long-term follow-up of
children treated for brain tumours from the endocrine point of view. Anticipation of hormone deficiencies and
replacement treatment can improve the quality of life of survivors.
Long-term survival following the treatment of brain tumours
in childhood has improved considerably over the past 30
years (Birch et al., 1988). For example, 50% 5-year survival
is reported in children with medulloblastoma treated by
surgery and post-operative craniospinal irradiation (Al Mefty
et al., 1985). A large, prospectively randomised study sug-
gested a role for chemotherapy, particularly in children with
adverse prognostic factors (Bloom & Thornton Jones, 1983).
It has become clear, however, that the large numbers of
children cured of their original tumour are at risk for long-
term sequelae, mainly from the radiotherapy (Shalet et al.,
1975; Harrop et al., 1976). Cranial irradiation may damage
the hypothalamo-pituitary axis leading to growth hormone
(GH) deficiency and other endocrine dysfunction. A small
number of studies have shown that spinal irradiation has an
adverse effect both on spinal growth (Probert et al., 1973;
Shalet et al., 1987) and on ovarian and thyroid function
(Brown et al., 1983; Shalet et al., 1977a; Oberfield et al.,
1986) and that some cytotoxic agents are gonadotoxic
(Ahmed et al., 1983; Livesey & Brook, 1988). There has been
no large unselected study of the prevalence of these disorders
and their implications.
Patients and methods
We have studied the long-term effects of treatment on 144
children (77 boys and 67 girls) treated for brain tumours at
two centres between 1972 and 1985. All were in clinical
remission following the treatment of a brain tumour not
involving the hypothalamo-pituitary region (Table I). Median
age at the start of the radiotherapy was 6.7 years (range
1.3-15) and median follow-up 9.6 years (2-26). After sur-
gical resection or biopsy whenever possible, all children
received megavoltage cranial irradiation employing a linear
accelerator in 49 patients and a cobalt-60 source in 95.
Eighty-seven children also received spinal irradiation using a
direct posterior field to treat the whole spine from the lower
border of the cerebral fields to S2 (Bloom, 1978). In order to
calculate with accuracy the dose of irradiation to the
hypothalamus its exact position had to be identified. As bony
relationships have never been established and anatomical
borders are not visible on planning films, CT brain scans
were used to define these in a sample of 40 children. These
observations were combined with the simulator or machine
check films and isodose distribution planes to estimate
hypothalamic dosimetry retrospectively without knowledge of
individual outcome.
Median calculated hypothalamic radiation dose was 48 Gy
(range 10-56) in 34 fractions (20-42) over 49 days (30-99).
Median spinal irradiation dose was 30 Gy (25-33) in 26
fractions (17-32) over 43 days (30-91). Thirty-four children
also received adjuvant chemotherapy, lomustine (CCNU),
vincristine and methotrexate singly or in combination.
Chemotherapy was combined with craniospinal irradiation in
30 children and with cranial irradiation in four. CCNU and
vincristine were generally given according to the schedules of
the International Society for Paediatric Oncology (SIOP)
(Bloom & Thornton Jones, 1983). Median total doses were
CCNU 650 mg m-2 (range 340-1200), vincristine 33 mg m2
(12-51) and methotrexate 3 gm2.
Observations of growth and puberty were made at varying
intervals after radiotherapy. Standing and sitting heights
(SH) were measured and subischial leg length (SILL) cal-
Table I Diagnosis
Medulloblastoma 60
Astrocytoma 34
Ependymoma 15
Glioma 11
Optic nerve glioma 11
Pineal tumour 8
Neuroectodermal tumour 3
Meningioma I
Oligodendroglioma I
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culated by subtraction. Measurements of basal serum concen-
trations of thyroid stimulating hormone (TSH), total thyrox-
ine, follicle stimulating hormone (FSH) and luteinsing hor-
mone (LH) were made in 138 children. Growth hormone
(GH) and cortisol secretion were assessed by insulin induced
hypoglycaemia (ITT) in 90 children growing below the 25th
height velocity centile (insulin 0.15 IU kg-' i.v.).
The normal serum GH concentration following hypo-
glycaemia was taken to be > 15 mU I'. Hormonal res-
ponses to intravenous gonadotrophin releasing hormone
(GnRH) 100ljg and thyrotrophin releasing hormone (TRH)
200jg were also measured in children undergoing ITT to
provide information about hypothalamo-pituitary gonadal
and thyroid function. Endocrine investigations were per-
formed at different intervals after radiotherapy or
chemotherapy when children were in clinical remission.
Primary thyroid dysfunction was defined as normal or
decreased serum total thyroxine concentration with elevated
serum TSH concentration. This was supported by an exag-
gerated TSH response to intravenous TRH. The normal
serum total thyroxine was 60-140 nmol 1' and basal serum
TSH concentration up to 4.8 mU I'. A subnormal serum
TSH concentration with decreased serum thyroxine concen-
tration indicated secondary thyroid dysfunction. Elevated
basal serum gonadotrophin concentration (LH or FSH
> 10 IU 1') accompanied by an exaggerated response to
GnRH were hallmarks or primary gonadal dysfunction.
Gonadotrophin deficiency was recognised by delayed or
arrested puberty combined with a failure of gonadotrophin
response to GnRH. Forty-nine children were treated with
GH at widely varying intervals after radiotherapy for periods
of 1-5 years.
Statistical analyses were made using the Mann-Whitney
and x2 tests.
Results
Growth andgrowth hormone
Thirty-three patients had completed their growth without
endocrine intervention, providing information about natural
history. Fourteen had received craniospinal irradiation and
19 cranial irradiation. The median ages of the two groups at
the time of radiotherapy were similar, 7 years (2.3-14.8) and
8.6 years (2.9-13) respectively. Figure 1 shows adult height,
sitting height and leg length standard deviation scores com-
pared to the normal population. It shows the highly
significant effect (P<0.001) of spinal irradiation on spinal
growth.
One hundred and twenty-four of 144 children (86%) of the
total group were found to have clinical and biochemical
evidence of GH insufficiency (GHI). The GH secretory status
of 16 children (11%) was unknown and four children (2.8%)
had normal growth.
Thyroiddysfunction
Primary thyroid dysfunction was present in 11 of 47 children
(23.4%) treated with craniospinal irradiation compared with
none of 39 given cranial irradiation alone. The association
with spinal irradiation was statistically significant (P<0.01).
Primary thyroid dysfunction was detected in 20 of 29 child-
ren (69%) treated with a combination ofcraniospinal irradia-
tion and chemotherapy and in two of four of those given
cranial irradiation with chemotherapy. The effect of
chemotherapy was highly significant (P<0.001). There was
no signficant difference in doses or duration ofchemotherapy
or age at treatment between affected and unaffected children.
Primary thyroid dysfunction was subclinical in the majority
of cases: the median serum TSH in affected children was
7.8mU 1' (range 5.9-37) with median thyroxine 76 nmol 1`
(range 10-118). Secondary thyroid dysfunction occurred in
four of 119 (3.4%) of the total group.
Gonadal dysfunction
All children have been included in the analysis although
gonadal dysfunction could not be excluded in prepubertal
children with normal basal serum gonadotrophin concentra-
tions (Winter & Faiman, 1972), so the true prevalence of
gonadal dysfunction may be higher than our data suggest.
Eighteen girls (26.8%) had evidence of primary gonadal dys-
function as evidenced by raised gonadotrophin concentra-
tions but only four boys (6.5%). Seven of 20 girls (35%) who
had been treated with spinal irradiation without
chemotherapy were affected and one of 37 boys (2.7%). Nine
of 15 girls (60%) given spinal irradiation and chemotherapy
were affected and three of 15 boys (20%). There was a
significant relationship between primary ovarian dysfunction
and spinal irradiation (P<0.01) but the increased incidence
in gonadal dysfunction after chemotherapy was not statis-
tically significant. However, two of three children given
chemotherapy without spinal irradiation had primary
gonadal dysfunction. No child given cranial irradiation alone
had primary gonadal dysfunction.
Gonadotrophin deficiency occurred in seven children of
pubertal age, all boys. Four had pineal tumours which are
known to impair gonadotrophin secretion.
ACTH
Only four of 90 children assessed had diminished cortisol
response to hypoglycaemia.
Growth hormone therapy
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Figure 1 Adult heights of 33 patients treated for brain tumours
in childhood (means ± s.e.m.). M, cranial irradiation (n = 19);
M, cranio-spinal irradiation (n = 14).
Forty-nine children have received GH for periods of between
1 and 5 years following demonstration of growth hormone
insufficiency (GHI) to ITT. Twenty-five prepubertal children
grew at a mean pretreatment height velocity of 3.5 cm year-'
(s.d. 1.2) after craniospinal irradiation and this increased to
6.8cm year-' (2.2) over the first year of treatment. Corres-
ponding figures for five prepubertal children after cranial
irradiation were 5.1 (1.2) and 9.5 (1.4). Table II shows the
effects of spinal irradiation and puberty on response.
Discussion
Treatment complications have become an increasingly impor-
tant consideration in children receiving radiotherapy or
chemotherapy for brain tumours. Endocrine complications
following cranial irradiation were recognised over 20 years
ago (Tan & Kunaratnam, 1966) but their degree is still
emerging. GHI is known to be common (Harrop et al.,
1976); we found that almost all children given cranial irradia-
tion had GHI when assessed by ITT. The resultant failure of
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Table II Effect ofirradiation on growth and the response to treatment in the first year
after initiation of GH therapy
Cranial irradiation Craniospinal irradiation
Prepubertal Pubertal Prepubertal Pubertal
Number of subjects 5 4 25 15
Height velocity (cm year-')
Pretreatment 5.1 (1.2) 3.8 (1.9) 3.5 (1.2) 3.4 (1.3)
1 year treatment 9.5 (1.4) 7.4 (4.3) 6.8 (2.2) 6.1 (2.1)
Height SDS for bone age
Pretreatment - 1.5 (1.7) + 0.1 (0.8) -0.5 (1.4) -0.7 (1.4)
1 year treatment -0.1 (1.2) + 0.3 (1.3) -0.1 (1.4) -1.0 (1.2)
Sitting height SDS for bone age
Pretreatment - 1.7 (1.1) -1.4 (0.4) -1.8 (1.4) -2.4 (1.8)
1 year treatment -0.5 (1.1) -1.3 (0.9) - 1.8 (1.5) - 2.4 (1.7)
Leg length SDS for bone age
Pretreatment + 0.1 (1.3) -0.5 (0.8) -0.9 (1.2) -0.5 (1.0)
I year treatment + 0.3 (0.3) -0.2 (1.0) -0.5 (1.2) -0.3 (1.2)
Values are means ± s.d. SDS = standard deviation score.
normal growth was compounded by the effects of spinal
irradiation on spinal growth.
Shalet established that the dose of radiation received by
the hypothalamopituitary axis was the determining factor for
GHI but a critical dose has not been identified (Shalet et al.,
1977b; Ahmed et al., 1986). In our study, affected children
received >40Gy to the hypothalamus in 20-40 fractions.
Those with normal growth received <30 Gy with similar
fractionation. There were insufficient children with normal
growth to establish a critical dose or regimen. We discovered
that the dose of irradiation to the hypothalamus cannot be
estimated, unless this region is individually defined. Ideally
this would be by prospective MRI studies. The dose to the
pituitary can differ significantly from that to the
hypothalamus. The methods used and difficulties experienced
in calculating hypothalamic doses do not seem to have been
addressed in previous studies.
If children are to maintain height relative to their peers,
they must grow close to the 50th height velocity centile and if
they grow persistently below the 25th velocity centile their
heights will deviate from those of their peers (Tanner et al.,
1966). Failulre to act upon a diminished height velocity while
the height of the child remains within the normal range has
led to delays in the institution of corrective GH therapy.
Effects of treatment are limited by the effect of spinal irradia-
tion and spinal growth is particularly important to height
achieved during the pubertal growth spurt. Thus GH needs
to be used while the contribution of leg growth remains
major, that is before puberty. Delay in instituting treatment
means that the effects of GH therapy are limited by fusion of
epiphyses. Delay in instituting treatment, poor spinal growth
following spinal irradiation and inadequate GH regimens
have probably all contributed to the poor reponses to GH
therapy reported (Shalet et al., 1981; Brauner et al., 1985).
Our current policy is to investigate and treat all patients
growing at a velocity less than the 25th centile one year after
completion of therapy for the primary disorder and to use at
least 15 U of growth hormone per m2 per week given by
daily subcutaneous injection. The assessment of velocity in
puberty is difficult because it depends on a detailed
knowledge of the interaction of puberty and growth: what
appears to be a normal velocity in a prepubertal child can be
the result ofprecocious sexual development for which clinical
signs have to be sought.
We found that deficiencies of other hypothalamo-pituitary
hormones were uncommon, although the possibility that
these may evolve must be considered (Eastman et al., 1979;
Samaan et al., 1982). Primary thyroid and primary gonadal
dysfunction were the commonest endocrine disorders after
GHI and occurred in a significant proportion of children
treated with spinal irradiation or chemotherapy.
Although spinal irradiation was the major aetiological fac-
tor in ovarian damage, chemotherapy was also gonadotoxic
(Livesey & Brook, 1988), an observation also made by
Ahmed et al. (1983). Delayed or arrested puberty occurred in
some affected children and normal pubertal development,
although sometimes with small final testicular volumes, was
seen in others. Other clinical consequences, which might
include infertility, premature osteoporosis and early
menopause, necessitate longer follow-up. Longer follow-up
may also show that we have underestimated the incidence of
primary gonadal dysfunction because of the difficulties in its
diagnosis before puberty.
The prevalence of primary thyroid dysfunction after spinal
irradiation ranged widely depending on whether
chemotherapy had also been given. There are no large studies
of primary thyroid dysfunction after the treatment of brain
tumours but prevalence rates between 25 and 60% have been
reported in children after craniospinal irradiation for medul-
loblastoma (Broadbent et al., 1981; Brown et al., 1983;
Oberfield et al., 1981). Some of these children had also
received chemotherapy. It is established that spinal irradia-
tion causes thyroid dysfunction but this is the first series to
have shown an association between chemotherapy and
primary thyroid dysfunction following the treatment of brain
tumours. Sutcliffe et al. (1981) found a high incidence of
primary thyroid dysfunction in adults treated for lymphomas
by chemotherapy alone.
Recognition of primary thyroid dysfunction depends on
the measurement of TSH concentrations and the understand-
ing that mild elevation is abnormal. The risk of thyroid
tumours after irradiation may be increased by a persistently
elevated serum TSH concentration (Lindsay et al., 1961;
Taylor, 1980). Our policy and that recommended by others
(Oberfield et al., 1986; Shalet et al., 1983) is to treat these
patients with thyroxine.
The prevalence of endocrine disorders described in this
large study confirms the importance of long-term follow-up
including regular observations of growth and appropriate
investigations. Anticipation of hormonal deficiences and
replacement treatment can improve the quality of life of
survivors.
This study was supported by the Cancer Research Campaign.
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